Literature DB >> 12531101

Inflammation in cystic fibrosis and its management.

G Döring1, D Worlitzsch.   

Abstract

Pulmonary complications are by far the most serious complications in cystic fibrosis (CF). In response to endobronchial bacterial infections, the long-term consequences of chronically activated polymorphonuclear leukocytes (neutrophils) are thought to cause loss of lung function and premature death. Effective anti-inflammatory therapy implies that we understand the complex networks of the immune response with its myriads of mediators on effector cells. We have many steps to go in this context, but science has already shed some light on inflammatory mechanisms in CF airways, and anti-inflammatory treatment strategies have been applied clinically with some success. The aim of this chapter is to review our present knowledge, and we will focus on early inflammation, bacterial persistence mechanisms, neutrophil activation, cytokines and nitric oxide together with anti-inflammatory treatment strategies in CF patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12531101     DOI: 10.1053/prrv.2000.0030

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  10 in total

1.  Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients.

Authors:  Neil E Alexis; Marianne S Muhlebach; David B Peden; Terry L Noah
Journal:  J Cyst Fibros       Date:  2005-12-13       Impact factor: 5.482

Review 2.  Targeting airway inflammation in cystic fibrosis in children: past, present, and future.

Authors:  Tacjana Pressler
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

3.  Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation.

Authors:  Amit Gaggar; Steven M Rowe; Hardision Matthew; J Edwin Blalock
Journal:  Open Respir Med J       Date:  2010-03-30

4.  Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography.

Authors:  Delphine L Chen; Thomas W Ferkol; Mark A Mintun; Jessica E Pittman; Daniel B Rosenbluth; Daniel P Schuster
Journal:  Am J Respir Crit Care Med       Date:  2006-03-16       Impact factor: 21.405

5.  Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator.

Authors:  Sam Tirkos; Susan Newbigging; Van Nguyen; Mary Keet; Cameron Ackerley; Geraldine Kent; Richard F Rozmahel
Journal:  Respir Res       Date:  2006-03-29

Review 6.  Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation.

Authors:  Carla M P Ribeiro; Bob A Lubamba
Journal:  Int J Mol Sci       Date:  2017-01-09       Impact factor: 5.923

7.  Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis.

Authors:  Olaf Eickmeier; Daniela Fussbroich; Klaus Mueller; Friederike Serve; Christina Smaczny; Stefan Zielen; Ralf Schubert
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

8.  Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies.

Authors:  Martina Gentzsch; Deborah M Cholon; Nancy L Quinney; Mary E B Martino; John T Minges; Susan E Boyles; Tara N Guhr Lee; Charles R Esther; Carla M P Ribeiro
Journal:  Front Pharmacol       Date:  2021-03-30       Impact factor: 5.810

9.  Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.

Authors:  Claus Moser; Maria Van Gennip; Thomas Bjarnsholt; Peter Østrup Jensen; Baoleri Lee; Hans Petter Hougen; Henrik Calum; Oana Ciofu; Michael Givskov; Søren Molin; Niels Høiby
Journal:  APMIS       Date:  2009-02       Impact factor: 3.205

10.  A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

Authors:  Amit Gaggar; Patricia L Jackson; Brett D Noerager; Philip J O'Reilly; D Brent McQuaid; Steven M Rowe; J P Clancy; J Edwin Blalock
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.